Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:41:27.851Z.
Calculation as of: 2026-10-06T15:41:27.851Z.
Quote observation: 2026-10-06T15:39:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc6ba70d6a7a815a92143918ed9b9c2f02635c4477fd12c4733392629ce909df
PE RATIO
N/A
Market Cap
$83.04M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | $85.17M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $85.21M | N/A | 8.03 | 8.03 | 8.03 |
| ProMIS Neurosciences, Inc. (PMN)vs › | $84.61M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.01M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $85.87M | N/A | 3.67 | 3.67 | 3.67 |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 29.23 | 45.53 | 45.53 | 24.63 |
| MediciNova, Inc. (MNOV)vs › | $83.18M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $83.04M | N/A | N/A | N/A | N/A |
| LENSAR Inc (LNSR)vs › | $82.66M | N/A | N/A | N/A | N/A |
| Nutriband Inc. (NTRB)vs › | $83.21M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.10
Forward EPS (Est.)
$-0.58
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
